James Barry
CIK 2022345 · View on SEC EDGAR ↗
First SEC filing: May 8, 2024 · Latest: May 8, 2024
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Sept. 4, 2024 | BIO | S | 623 | $330.49 | $205,895 | 147 Direct | -80.91% | Disposed | 9.9% (price as of 2026-08-19) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| March 3, 2025 | BIO | Non-Qualified Stock Option (right to buy) | Bio-Rad A Common Stock (2,918) | $256.45 | March 3, 2035 | 2,918 | Acquired |
| Sept. 6, 2024 | BIO | Restricted Stock Units | Bio-Rad A Common Stock (4,224) | — | — | 4,224 | Acquired |
| Sept. 3, 2024 | BIO | Restricted Stock Units | Bio-Rad A Common Stock (217) | — | — | 217 | Disposed |
| Sept. 2, 2024 | BIO | Restricted Stock Units | Bio-Rad A Common Stock (265) | — | — | 265 | Disposed |
| Sept. 1, 2024 | BIO | Restricted Stock Units | Bio-Rad A Common Stock (177) | — | — | 177 | Disposed |
| Sept. 1, 2024 | BIO | Restricted Stock Units | Bio-Rad A Common Stock (173) | — | — | 173 | Disposed |
| Sept. 1, 2024 | BIO | Restricted Stock Units | Bio-Rad A Common Stock (250) | — | — | 250 | Disposed |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 7 holdings
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| May 8, 2024 | BIO | Bio-Rad A Common Stock | 31 | Direct |
| May 8, 2024 | BIO | Restricted Stock Units→ Bio-Rad A Common Stock (217) | 217 | Direct |
| May 8, 2024 | BIO | Restricted Stock Units→ Bio-Rad A Common Stock (265) | 265 | Direct |
| May 8, 2024 | BIO | Restricted Stock Units→ Bio-Rad A Common Stock (355) | 355 | Direct |
| May 8, 2024 | BIO | Restricted Stock Units→ Bio-Rad A Common Stock (521) | 521 | Direct |
| May 8, 2024 | BIO | Restricted Stock Units→ Bio-Rad A Common Stock (1,002) | 1,002 | Direct |
| May 8, 2024 | BIO | Non-Qualified Stock Option (right to buy)→ Bio-Rad A Common Stock (1,179) | 1,179 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
BIO
President, Life Science Group| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2025 | $536,752 | — | — | — | $266,079 | — | $303,685 | $2,611,227 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.